A Study Of PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

A Randomized Phase 2 Non-Comparative Study Of The Efficacy Of PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer(B1271004)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221700

Enrollment

252

Registered

2012-01-24

Start date

2012-01-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Neoplasms

Interventions

investigational material(s) Generic name etc : PF-04691502 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mate

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: - Recurrent endometrial carcinoma - Disease progression following one or two lines of prior treatment with platinum containing chemotherapy - Tumor tissue available at time of screening for PI3K analysis - Adequate glucose control, bone marrow, kidney, liver, and heart function

Exclusion criteria

Exclusion criteria: - More than 2 prior cytotoxic chemo regimens for endometrial carcinoma - Prior therapy with an agent known to be a PI3K, and or mTOR and or AKT inhibitor - Active brain metastases

Design outcomes

Primary

Measure	Time frame
efficacy Clinical Benefit Rate (CBR) To assess 16 weeks for CBR	—

Secondary

Measure	Time frame
safety efficacy pharmacokinetics - Objective Response Rate (ORR) - Overall Survival (OS) - Progression Free Survival (PFS) - PFS at 6 months - Pharmacokinetics (PK) To assess 12 months for ORR, OS, PFS, and 6 months for PFS and PK	—

Countries

Europe, Japan, North America, Oceania

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026